Metraipolis › archive › dc_03fdc697f2fd

Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma — Europe PMC PMID:41599648

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41599648
DOI: 10.3390/ph19010047
License (as archived): solo-consultazione
Archived: 2026-11-07T10:11:35.210Z
SHA-256 of the archived text: 5023ef9766c240cb40fdd6aaf3748f7cf7dcae0fc53bcedf8b61b07182a79c96
Stable URL of this page: https://metraipolis.com/documento/dc_03fdc697f2fd

How to cite

Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma — Europe PMC PMID:41599648 — Europe PMC (en), https://europepmc.org/article/MED/41599648 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_03fdc697f2fd (Metraipolis archive dc_03fdc697f2fd, sha256 5023ef9766c240cb40fdd6aaf3748f7cf7dcae0fc53bcedf8b61b07182a79c96)

BibTeX

@misc{dc03fdc697f2fd,
  title = {Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma — Europe PMC PMID:41599648},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41599648},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_03fdc697f2fd; sha256 5023ef9766c240cb40fdd6aaf3748f7cf7dcae0fc53bcedf8b61b07182a79c96},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41599648. Agents can read the archived copy with the MCP tool read_document.